KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $19.4 billion.

  • Teva Pharmaceutical Industries' Total Non-Current Liabilities fell 687.2% to $19.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $19.4 billion, marking a year-over-year decrease of 687.2%. This contributed to the annual value of $19.4 billion for FY2025, which is 687.2% down from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Total Non-Current Liabilities stood at $19.4 billion, which was down 687.2% from $21.1 billion recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Total Non-Current Liabilities ranged from a high of $25.9 billion in Q1 2021 and a low of $19.4 billion during Q4 2025
  • For the 5-year period, Teva Pharmaceutical Industries' Total Non-Current Liabilities averaged around $23.1 billion, with its median value being $23.3 billion (2022).
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Total Non-Current Liabilities soared by 43.51% in 2023, and later crashed by 1266.19% in 2024.
  • Teva Pharmaceutical Industries' Total Non-Current Liabilities (Quarter) stood at $25.4 billion in 2021, then decreased by 5.71% to $23.9 billion in 2022, then dropped by 3.5% to $23.1 billion in 2023, then dropped by 9.94% to $20.8 billion in 2024, then fell by 6.87% to $19.4 billion in 2025.
  • Its Total Non-Current Liabilities stands at $19.4 billion for Q4 2025, versus $21.1 billion for Q3 2025 and $21.4 billion for Q2 2025.